Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
List view / Grid view
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
Lung spheroid cells can act as nanodecoys for the SARS-CoV-2 Spike protein to bind to, according to a new pre-clinical study.
Scientists say COVID-19 may activate tuberculosis infection, but stem cell-mediated defence mechanisms could be targeted to develop vaccines.
Researchers have shown that the leakage of mitochondrial double-stranded DNA into the cell can contribute to Parkinson's disease.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
Scientists have developed an implant that releases insulin-secreting cells which has shown success at treating diabetes in mice.
A new DNA vaccine encoding the SARS-CoV-2 Spike protein has shown promise at protecting mice and hamsters against COVID-19.
Researchers have shown that inhalable nanobodies at ultra-low doses can effectively neutralise SARS-CoV-2 in hamsters.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.